Cardiol Therapeutics Inc (NASDAQ:CRDL) shares, rose in value on Wednesday, June 18, with the stock price down by -3.65% to the previous day’s close as strong demand from buyers drove the stock to $1.32.
Actively observing the price movement in the last trading, the stock closed the session at $1.37, falling within a range of $1.31 and $1.37. The value of beta (5-year monthly) was 0.763. Referring to stock’s 52-week performance, its high was $2.63, and the low was $0.77. On the whole, CRDL has fluctuated by 17.86% over the past month.
With the market capitalization of Cardiol Therapeutics Inc currently standing at about $109.10 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-May-14.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that CRDL’s technical picture suggests that short-term indicators denote the stock is a 50% Buy on average. However, medium-term indicators have put the stock in the category of 50% Sell while long-term indicators on average have been pointing out that it is a Hold.
The stock’s technical analysis shows that the price of CRDL currently trading nearly 0.49% and 13.40% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 52.45, while the 7-day volatility ratio is showing 2.55% which for the 30-day chart, stands at 4.49%. Furthermore, Cardiol Therapeutics Inc (CRDL)’s beta value is 1.02, and its average true range (ATR) is 0.09.
A comparison of Cardiol Therapeutics Inc (CRDL) with its peers suggests the former has fared considerably weaker in the market. CRDL showed an intraday change of -3.65% in last session, and over the past year, it shrunk by -45.23%%.
Data on historical trading for Cardiol Therapeutics Inc (NASDAQ:CRDL) indicates that the trading volumes over the past 10 days have averaged 0.23 and over the past 3 months, they’ve averaged 196.15K. According to company’s latest data on outstanding shares, there are 82.61 million shares outstanding.
Nearly 4.78% of Cardiol Therapeutics Inc’s shares belong to company insiders and institutional investors own 9.57% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.99 million shares as on 2025-05-30, resulting in a short ratio of 12.79. According to the data, the short interest in Cardiol Therapeutics Inc (CRDL) stood at 250.00 of shares outstanding as of 2025-05-30; the number of short shares registered in 2025-04-30 reached 2.02 million. The stock has risen by 3.13% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the CRDL stock heading into the next quarter.
